RxDoctor Payments Data

Arunpreet Kahlon

Interventional Cardiology · Lone Tree, CONPI 1437582202

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (48.3%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 48 manufacturers reported payments, led by Penumbra, Inc. at 44.2% of the total.

$36,874in general payments, 2019–2025

Across 420 payments — averaging $87.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Penumbra, Inc.$16K
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$7K
  • Medtronic$2K
  • Abbott$1K
  • Boston Scientific$1K
  • Inari Medical, Inc.$1K
  • plus $7K from 42 others

What the payments were for

  • Speaking & faculty fees$17,80048%
  • Travel & lodging$4,92813%
  • Food & beverage$13,67737%
  • Education$4691%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$36,874 in reported general payments places this provider in the 80th percentile of 111 interventional cardiology providers in Colorado.

See all interventional cardiology providers in Colorado

Medicare billing

Part B allowed, 2024
$292,033
Medicare patients
1,038
Services billed
6,489

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban156$222,708
FarxigaDapagliflozin Propanediol76$80,825
OzempicSemaglutide39$57,872
JardianceEmpagliflozin33$48,570
XareltoRivaroxaban34$37,020
MounjaroTirzepatide30$33,781
EntrestoSacubitril/Valsartan15$25,994
Repatha SureclickEvolocumab31$25,346
WegovySemaglutide16$22,896
Ranolazine ErRanolazine37$4,413
Prasugrel Hcl24$3,587
Metoprolol Succinate211$2,880
Rosuvastatin Calcium244$2,583
Ezetimibe56$2,162
Eplerenone14$1,427

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$403$222,708156 claims
AstraZenecaFarxiga$312$80,82576 claims
Novo NordiskOzempic, Wegovy$469$80,76855 claims
Boehringer IngelheimJardiance$303$48,57033 claims
Johnson & JohnsonXarelto$73$37,02034 claims
Lilly USA, LLCMounjaro$49$33,78130 claims
NovartisEntresto$719$25,99415 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 111 interventional cardiology providers in Colorado.

Other interventional cardiology in Lone Tree

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →